Cornerstone Planning LLC Invests $3.08 Million in Merck & Co., Inc. $MRK

Cornerstone Planning LLC bought a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 29,204 shares of the company’s stock, valued at approximately $3,085,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Chesapeake Wealth Management lifted its position in shares of Merck & Co., Inc. by 0.6% during the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after acquiring an additional 87 shares during the last quarter. South Plains Financial Inc. grew its holdings in shares of Merck & Co., Inc. by 0.6% in the 4th quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock worth $1,635,000 after acquiring an additional 89 shares during the last quarter. Syverson Strege & Co grew its holdings in shares of Merck & Co., Inc. by 2.2% in the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock worth $436,000 after acquiring an additional 90 shares during the last quarter. Westside Investment Management Inc. raised its position in shares of Merck & Co., Inc. by 3.1% during the fourth quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock worth $331,000 after purchasing an additional 93 shares during the period. Finally, Valued Wealth Advisors LLC raised its position in shares of Merck & Co., Inc. by 26.9% during the fourth quarter. Valued Wealth Advisors LLC now owns 444 shares of the company’s stock worth $47,000 after purchasing an additional 94 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $114.04 on Friday. The company has a market capitalization of $281.65 billion, a price-to-earnings ratio of 32.12, a P/E/G ratio of 2.56 and a beta of 0.21. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $125.14. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The business’s 50-day moving average is $115.94 and its 200-day moving average is $113.60.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same period last year, the company posted $2.22 earnings per share. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities research analysts expect that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s payout ratio is currently 95.77%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. UBS Group increased their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Wells Fargo & Company decreased their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. Finally, Citigroup began coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $128.18.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.